AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

January 7, 2020 GMT

VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan 7, 2020--

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present a corporate overview and updated clinical development plans for its lead candidates ZW25 and ZW49 at the upcoming 38 th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3:30 p.m. PT.

The presentation will be webcast live and available for replay on Zymeworks’ website at  http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit  www.zymeworks.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200107005169/en/

CONTACT: Investor Inquiries:

Ryan Dercho, Ph.D.

(604) 678-1388

ir@zymeworks.comTiffany Tolmie

(604) 678-1388

ir@zymeworks.comMedia Inquiries:

Kavita Shah, Ph.D.

(604) 678-1388

media@zymeworks.com

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Zymeworks Inc.

Copyright Business Wire 2020.

PUB: 01/07/2020 08:30 AM/DISC: 01/07/2020 08:30 AM

http://www.businesswire.com/news/home/20200107005169/en